-
Views
-
Cite
Cite
M M Prata, C Madeira, O Vicente, M J Miguel, Lipid profile in haemodialysis patients treated with recombinant human erythropoietin., Nephrology Dialysis Transplantation, Volume 13, Issue 9, Sep 1998, Pages 2345–2347, https://doi.org/10.1093/ndt/13.9.2345
- Share Icon Share
Abstract
BACKGROUND: The long-term effect of recombinant human erythropoietin (rhEPO) on the blood-lipid profile has not been well documented. The aim of this study was to evaluate whether rhEPO therapy affects the lipid pattern. METHODS: A group of 102 maintenance haemodialysis patients were treated for 2 years with rhEPO given intravenously at the end of the dialysis session. Attempts were made to keep the haemoglobin (Hb) at 10-11 g/dl and/or the haematocrit (Hct) at 30-35%. Twenty maintenance haemodialysis patients not treated with rhEPO were examined as controls. Total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, apolipoproteins A1 and B, and lipoprotein (a)[Lp (a)] were assessed at baseline (without rhEPO), and 1 and 2 years after the beginning of treatment. Hb, Hct and ferritin were measured monthly, and Kt/v was evaluated monthly and kept above 1.1. RESULTS: During follow-up, in both groups, there was a significant increase in Apo A1 and no significant changes in the other lipid parameters. In the treated group, Hb and Hct increased significantly after the fourth month of treatment. CONCLUSIONS: Erythropoietin therapy does not affect significantly the levels of total cholesterol, LDL- and HDL-cholesterol, triglycerides, Apo B and Lp (a) in maintenance hemodialysis patients.
- apolipoproteins
- hemodialysis
- ldl cholesterol lipoproteins
- high density lipoprotein cholesterol
- triglycerides
- lipoproteins
- erythropoietin therapy
- hemoglobin
- apolipoproteins b
- recombinant erythropoietin
- follow-up
- apolipoprotein a-i
- ferritin
- hematocrit procedure
- hematocrit
- lipids
- fasting lipid profile
- total cholesterol
Comments